DHRNYSEIndustrial Instruments For Measurement, Display, and ControlFiscal year ends December 31
DANAHER CORP /DE/
Financials through Q2 FY2026, quarter ended Jun 26, 2026Last filing: 10-Q on Jul 21, 2026
$224.43−4.61 (-2.01%)
Close on Oct 19, 2026
- Market cap
- $158.81B
- P/E (TTM)
- 39.9
- Dividend yield
- –
DANAHER CORP /DE/ revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diagnostics | $9.94B | $9.79B | $9.58B | – | – | – | – | – | – | – | 40.5% | +1.6% |
| Life Sciences | $7.33B | $7.33B | $7.14B | – | – | – | – | – | – | – | 29.9% | +0.1% |
| Biotechnology | $7.29B | $6.76B | $7.17B | – | – | – | – | – | – | – | 29.7% | +7.9% |
| Dental | – | – | – | – | – | – | – | $2.84B | $2.81B | $2.79B | – | – |
| Diagnostics | – | $9.79B | $9.58B | $10.85B | $9.84B | $7.40B | $6.56B | $6.26B | $5.84B | $5.04B | – | – |
| Environmental & Applied Solutions | – | – | – | $4.80B | $4.65B | $4.31B | $4.40B | $4.32B | $3.97B | $3.69B | – | – |
| Life Sciences | – | $7.33B | $7.14B | $7.04B | $6.39B | $5.30B | $6.95B | $6.47B | $5.71B | $5.37B | – | – |
| Biotechnology | – | $6.76B | $7.17B | $8.76B | $8.57B | $5.28B | – | – | – | – | – | – |
| Operating income | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Diagnostics | $2.65B | $2.63B | $2.41B | – | – | – | – | – | – | – | +1.0% |
| Biotechnology | $1.86B | $1.69B | $1.91B | – | – | – | – | – | – | – | +10.6% |
| Life Sciences | $520.00M | $879.00M | $1.21B | – | – | – | – | – | – | – | -40.8% |
| Dental | – | – | – | – | – | – | – | $346.70M | $400.70M | $419.40M | – |
| Diagnostics | – | $2.63B | $2.41B | $3.44B | $2.31B | $1.54B | $1.13B | $1.07B | $871.60M | $786.40M | – |
| Environmental & Applied Solutions | – | – | – | $1.14B | $1.05B | $979.00M | $1.05B | $988.00M | $914.60M | $870.00M | – |
| Life Sciences | – | $879.00M | $1.21B | $1.41B | $1.29B | $972.00M | $1.40B | $1.23B | $1.00B | $818.90M | – |
| Biotechnology | – | $1.69B | $1.91B | $3.01B | $3.07B | $1.08B | – | – | – | – | – |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Recurring revenue | $20.13B | $19.37B | $18.68B | $20.88B | $19.14B | $15.98B | $12.31B | $11.68B | – | – | 81.9% | +3.9% |
| Nonrecurring revenue | $4.44B | $4.51B | $5.21B | $5.77B | $5.67B | $6.31B | $5.60B | $5.37B | – | – | 18.1% | -1.5% |
| Product Identification | – | – | – | $1.98B | $2.03B | $1.86B | $1.94B | $1.93B | $1.77B | $1.64B | – | – |
| Analytical and physical instrumentation | – | – | – | $2.85B | $2.62B | $2.44B | $2.46B | $2.44B | $2.23B | $2.09B | – | – |
| Dental products | – | – | – | – | – | – | – | $2.84B | $2.81B | $2.79B | – | – |
| Research and medical products | – | – | – | $26.64B | $24.80B | $17.98B | $13.51B | $12.69B | $11.51B | $10.37B | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| North America | $10.36B | $10.30B | $9.96B | $11.73B | $9.80B | $9.01B | $7.01B | $6.47B | – | – | 42.2% | +0.6% |
| High-growth markets | $7.02B | $6.87B | $7.19B | $7.71B | – | – | – | – | – | – | 28.6% | +2.2% |
| Western Europe | $5.94B | $5.46B | $5.47B | $5.86B | $5.88B | $5.32B | $4.06B | $4.06B | – | – | 24.2% | +8.8% |
| Other developed markets | $1.25B | $1.25B | $1.27B | $1.35B | – | – | – | – | – | – | 5.1% | -0.1% |
| High-growth markets | – | – | $7.19B | $7.71B | $7.77B | $6.65B | $5.73B | $5.44B | – | – | – | – |
| Other developed markets | – | – | $1.27B | $1.35B | $1.36B | $1.30B | $1.11B | $1.08B | – | – | – | – |
From the segment and revenue-disaggregation notes of Danaher's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.